MDACC Study No:2011-0800 ( NCT No: NCT01504126)
Title:Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Principal Investigator:Lois M. Ramondetta
Treatment Agent:Carboplatin; Docetaxel; Paclitaxel; Propranolol
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if it is feasible to give
a beta-blocker such as Inderal (propranolol hydrochloride) with standard
chemotherapy (paclitaxel and carboplatin or possibly docetaxel) to treat
ovarian cancer. The safety of propranolol hydrochloride will also be studied.

Propranolol hydrochloride is designed to block certain chemicals that affect
the heart. Researchers want to learn if this might also boost the immune
system, allowing the chemotherapy to be more effective.

Paclitaxel is designed to block cancer cells from dividing, which may cause
them to die.

Carboplatin is designed to interfere with the growth of cancer cells by
stopping cell division, which may cause the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:N/A
Treatment Agents:Carboplatin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sprint for Life 5/2011
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Lois M. Ramondetta
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-0307
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults